牛牛AI助理已提取核心讯息长江生命科技集团于2025年上半年度录得股东应占亏损1.51亿港元,相较去年同期盈利100万港元转亏。亏损主要由于公司大幅增加研发投资,由去年同期的7,290万港元提升至2.35亿港元,增幅达1.62亿港元。若研发开支维持去年水平,期内净溢利将较去年同期略增1,060万港元。董事会不派发中期股息。公司医药科研取得重要进展,其中黑色素瘤疫苗seviprotimut-L正进行...
Source Link牛牛AI助理已提取核心讯息长江生命科技集团于2025年上半年度录得股东应占亏损1.51亿港元,相较去年同期盈利100万港元转亏。亏损主要由于公司大幅增加研发投资,由去年同期的7,290万港元提升至2.35亿港元,增幅达1.62亿港元。若研发开支维持去年水平,期内净溢利将较去年同期略增1,060万港元。董事会不派发中期股息。公司医药科研取得重要进展,其中黑色素瘤疫苗seviprotimut-L正进行...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.